EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Treatment Outcomes and Toxicity Profiles with PORTEC-3 Trial Regimen in South Asian Cohort of High-Risk Endometrial Cancer Patients: A Single-Center Ambispective Analysis

Behandlungsoutcomes und Toxizitätsprofile unter dem PORTEC-3-Schema bei südasiatischen Patient:innen mit Hochrisiko-Endometriumkarzinom: monozentrische ambispektive Analyse

Parth Verma, Rajasree Rajan, Ajay Sasidharan, Sruthi Kalavagunta iD, Debnarayan Dutta, Beena Kunheri, Neethu Kunnath, Priya Bhati, Anupama Rajanbabu, Indu Nair, Rakesh Moolayil Puthenveedu iD, Nikhil Haridas iD und 2 weitere

South Asian Journal of Cancer · 01.07.2025 · 14 (03) · 485-492

DOI: 10.1055/s-0044-1789606 ↗

Auf einen Blick

Bei 58 Patient:innen mit Hochrisiko-Endometriumkarzinom war die adjuvante Chemoradiochemotherapie meist durchführbar. Während der Bestrahlung kam es zu keiner therapiebedingten Unterbrechung.

Fragestellung

Beschreibung von Toxizität und Outcomes unter adjuvanter Chemoradiochemotherapie gefolgt von Chemotherapie bei südasiatischen Patient:innen mit Hochrisiko-Endometriumkarzinom.

Methode

Monozentrische ambispektive Analyse; Toxizität nach RTOG- und CTCAE-Kriterien; DFS und OS nach Kaplan-Meier, Vergleich per Log-Rank-Test, Cox-Regression für DFS-Prädiktoren.

Ergebnisse

58 Patient:innen. Akute Toxizität Grad ≥ 2 unter Chemoradiation: Diarrhö 17,2 %, hämatologisch 3,4 %. 51/55 beendeten 4 Zyklen Chemotherapie. 5-Jahres-DFS 63,8 %, OS 76,5 %.

Schlussfolgerung der Autor:innen

Die Autor:innen berichten eine gute Verträglichkeit und Compliance der adjuvanten Chemoradiochemotherapie und Chemotherapie in dieser südasiatischen Kohorte; die Befunde entsprachen den Ergebnissen der PORTEC-3-Studie.

Kernaussagen

  • Keine therapiebedingten Behandlungsabbrüche während der Bestrahlung
  • 15/58 Rezidive bei median 31 Monaten Nachbeobachtung
  • 5-Jahres-DFS 63,8 %; 5-Jahres-OS 76,5 %

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift South Asian Journal of Cancer, erschienen am 01.07.2025. Verfasst von Parth Verma und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Amrita Institute of Medical Sciences, Kochi, India. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adjuvant chemoradiation followed by chemotherapy is the current standard of care in high-risk endometrial cancer after the PORTEC-3 trial. There is a lack of data on this treatment regimen in the South Asian patient cohort. The present study aims to assess toxicity profiles and outcomes in this cohort of patients. High-risk endometrial cancer patients planned for adjuvant chemoradiation followed by chemotherapy were included. Toxicity was graded using the Radiation Therapy Oncology Group and Common Terminology Criteria for Adverse Events criteria. Disease-free survival (DFS) and overall survival (OS) were estimated using the Kaplan–Meier method. Survival curves were compared using the log-rank test. Cox regression analysis was done to find out the predictors of DFS. This study included 58 patients treated from October 2016 to August 2022. Median age was 61 years (interquartile range [IQR] 56–66), with Fédération Internationale de Gynécologie et d'Obstétrique Stages I = 26 (44.8%), II = 5 (8.6%), and III = 27 (46.6%). p53 positivity was seen in 38 (65.5%) patients. Intensity-modulated radiotherapy was used in 44 (79.3%) patients. There was no treatment discontinuation during chemoradiation. Acute Grade 2 and above toxicity during chemoradiation were diarrhea in 10 (17.2%) and hematological in 2 (3.4%). For the planned adjuvant chemotherapy in 55 patients, 51 (92.7%) completed four cycles. Grade 2 or above neuropathy was seen in 11 (20%), with 5 (9%) having persisting neuropathy at 1-year follow-up. At a median follow-up of 31 months, 15 (25.8%) patients recurred; distant = 13 and isolated para-aortic = 2. The median time to recurrence was 16 months (IQR 12–22), with 80% (12 out of 15) of recurrence within the first 2 years of follow-up. The actuarial 5-year DFS and OS were 63.8 and 76.5%, respectively. In univariate analysis, p53 positivity and lymphovascular space invasion were predictors for DFS, with p-values 0.031 and 0.027, respectively. There was no significant predictor identified in multivariate analysis. There is good tolerance and compliance to adjuvant chemoradiation and chemotherapy in this South Asian cohort of patients with high-risk endometrial cancer, with no toxicity-related treatment breaks during radiation. The majority of the recurrences were seen at distant sites and within the first 2 years of follow-up. These findings are in line with the outcomes of the PORTEC-3 trial.

Schlagwörter

Stichwörter der Autor:innen

South Asianendometrial cancerhigh riskoutcometoxicity

Autor:innen und Institutionen

  • Department of Radiation Oncology, Amrita Institute of Medical Sciences, Kochi, India.
  • Department of Gynec Oncology, Amrita Institute of Medical Sciences, Kochi, India.
  • Department of Pathology, Amrita Institute of Medical Sciences, Kochi, India.
  • Department of Medical Oncology, Amrita Institute of Medical Sciences, Kochi, India.

ORCID-Profile: Sruthi Kalavagunta, Rakesh Moolayil Puthenveedu, Nikhil Haridas, Wesley Jose, Keechilat Pavithran

Zitieren

APA

Verma, P., Rajan, R., Sasidharan, A., Kalavagunta, S., Dutta, D., Kunheri, B., Kunnath, N., Bhati, P., Rajanbabu, A., Nair, I., Puthenveedu, R. M., Haridas, N., Jose, W., & Pavithran, K. (2025). Treatment Outcomes and Toxicity Profiles with PORTEC-3 Trial Regimen in South Asian Cohort of High-Risk Endometrial Cancer Patients: A Single-Center Ambispective Analysis. South Asian Journal of Cancer, 14(03), 485-492. https://doi.org/10.1055/s-0044-1789606

Vancouver

Verma P, Rajan R, Sasidharan A, Kalavagunta S, Dutta D, Kunheri B, et al. Treatment Outcomes and Toxicity Profiles with PORTEC-3 Trial Regimen in South Asian Cohort of High-Risk Endometrial Cancer Patients: A Single-Center Ambispective Analysis. South Asian Journal of Cancer. 2025;14(03):485-492. doi:10.1055/s-0044-1789606

BibTeX
@article{Verma2025,
  author = {Verma, Parth and Rajan, Rajasree and Sasidharan, Ajay and Kalavagunta, Sruthi and Dutta, Debnarayan and Kunheri, Beena and Kunnath, Neethu and Bhati, Priya and Rajanbabu, Anupama and Nair, Indu and Puthenveedu, Rakesh Moolayil and Haridas, Nikhil and Jose, Wesley and Pavithran, Keechilat},
  title = {Treatment Outcomes and Toxicity Profiles with PORTEC-3 Trial Regimen in South Asian Cohort of High-Risk Endometrial Cancer Patients: A Single-Center Ambispective Analysis},
  journal = {South Asian Journal of Cancer},
  year = {2025},
  volume = {14},
  number = {03},
  pages = {485--492},
  doi = {10.1055/s-0044-1789606}
}
Kostenlos starten →